semaglutide cardiovascular outcomes news today 2025 align more closely with attained dose than achieved weight loss Cardiovascular outcomes of semaglutide and

Both semaglutide and tirzepatide are administered via weekly subcutaneous injections, and both have proven efficacy for weight loss

[15] Semaglutide is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain, and acts as a GLP-1 receptor agonist

Gastrointestinal issues top the list of concerns, but gallbladder symptoms, thyroid cancer risks, and mental health questions are all part of the evolving safety profile

Lilly does not promote or encourage use of any Lilly medicine outside of its FDA-approved indication. GLP-1 drugs and binge eating While some people with disordered eating over-restrict, others can binge to deal with stress or difficult emotions

Theyll create a custom plan and keep you motivated